Charter Research & Investment Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Charter Research & Investment Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$373K	Hold	4,275	–	–	0.44%	53
2016 Q2	$368K	Sell	4,275 -100	-2%	-$8.64K	0.42%	55
2016 Q1	$348K	Hold	4,375	–	–	0.4%	54
2015 Q4	$551K	Hold	4,375	–	–	0.64%	42
2015 Q3	$456K	Buy	4,375 +25	+0.6%	+$3.21K	0.6%	41
2015 Q2	$537K	Hold	4,350	–	–	0.6%	42
2015 Q1	$513K	Hold	4,350	–	–	0.57%	43
2014 Q4	$517K	Buy	+4,350	New	+$490K	0.57%	45

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Charter Research & Investment Group's VRTX Position: Q3 2016 in Review

Charter Research & Investment Group held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2016 at 4,275 shares worth $373K. The position accounts for 0.44% of the portfolio, ranked #53.

Charter Research & Investment Group first reported a position in VRTX in Q4 2014 and has held it in 8 quarters since. The position peaked at $551K in Q4 2015. 491 funds tracked by Wall St. Rank hold VRTX as of Q3 2016.

Charter Research & Investment Group held 4,275 shares of Vertex Pharmaceuticals worth $373K as of Q3 2016.
Charter Research & Investment Group left its Vertex Pharmaceuticals share count unchanged in Q3 2016.
Vertex Pharmaceuticals made up 0.44% of Charter Research & Investment Group's portfolio in Q3 2016, its #53 holding.
Charter Research & Investment Group first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 8 quarters since.
Charter Research & Investment Group's Vertex Pharmaceuticals position peaked at $551K in Q4 2015.
491 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2016.

Based on Charter Research & Investment Group's 13F filing for Q3 2016, filed 14 Nov 2016.